Polatuzumab vedotin-R-CHP used for high-risk EBV-negative DLBCL-type post-transplant lymphoproliferative disorder in a long-term kidney transplant recipient: a case report
In this case, Pola-R-CHP achieved a favorable initial response, suggesting a potential role in the management of mPTLD. However, the subsequent central nervous system relapse underscores the need for further studies that incorporating CNS prophylaxis to define its optimal application.
Authors
- Yuxun Oswald Zhang (ORCID: https://orcid.org/0000-0002-7315-6204)
- Xiaoyu Jiang (ORCID: https://orcid.org/0000-0002-3517-9843)
- Yiwen Qiu (ORCID: https://orcid.org/0000-0003-0022-4824)
- Lianshan Zhan
- Mingqing Luo
- Chunping Wu
- Daping Zhong
- Miao Li
Institutions
- Guizhou Education University (CN)
- Guizhou Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.3389/fonc.2025.1673495
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00